PMID 2358087 2358087 DOI 10.1016/s0015-0282(16)53661-9 10.1016/s0015-0282(16)53661-9
Cite this article
Abraham, G. E., & Hargrove, J. T. (1990). Diagnosis and treatment of premenstrual syndrome. Fertility and Sterility, 54(1), 178-179. https://doi.org/10.1016/s0015-0282(16)53661-9
Abraham GE, Hargrove JT. Diagnosis and treatment of premenstrual syndrome. Fertil Steril. 1990;54(1):178-179. doi:10.1016/s0015-0282(16)53661-9
Abraham, G. E., and J. T. Hargrove. "Diagnosis and treatment of premenstrual syndrome." Fertility and Sterility, vol. 54, no. 1, 1990, pp. 178-179.
To investigate the efficacy and safety of open-label placebos (OLP) in premenstrual syndrome (PMS).
Randomised controlled trial.
Switzerland, 2018-2020. 150 women (18-45 years of age) with PMS or premenstrual dysphoric disorder. Random assignment (1:1:1) to treatment as usual (TAU), OLP without treatment rationale (OLP-), or OLP with treatment rationale (OLP+). OLP consisted of two placebo pills per day for 6 weeks. Primary outcomes were PMS symptom intensity and interference between groups across three menstrual cycles (MC1-MC3); adverse events (ie, safety) were measured at weeks 3 and 6 after the start of the intervention. Secondary outcomes were psychological and somatic subscales of PMS symptom intensity, and adherence. From 2 August 2018 to 3 December 2020,
Women diagnosed as suffering from premenstrual syndrome and symptom free controls were compared on hormonal parameters, glucose tolerance, mineralocorticoids, cholesterols, triglycerides, apolipoprotein (a), magnesium and calcium in the follicular and luteal phases of the menstrual cycle. The effect of treatment with essential fatty acids on the biochemical variables was also evaluated in a randomized, double-blind crossover design. The results showed that the hormonal and biochemical profiles of women with PMS and symptom free controls were markedly similar, except for aldosterone which was lower in the follicular and luteal phases and cholesterol which was higher in the follicular phase in women with PMS. No effects of treatment with essential fatty acids were found for any of the biochemical variables studied.
Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the Society for Reproductive Endocrinology and Infertility, 2026·Fertility and sterility
Luteal phase deficiency (LPD) is a clinical diagnosis associated with abnormal luteal phase length of ≤10 days. Potential etiologies of LPD include inadequate progesterone duration, inadequate progesterone levels, or endometrial progesterone resistance. Luteal phase deficiency has been described in association with medical conditions, but also in fertile, normally menstruating women. Although progesterone is important for the process of implantation and early embryonic development, LPD has not been proven to be an independent entity causing infertility or recurrent pregnancy loss. Controversy exists regarding the multiple proposed measures for diagnosing LPD, and assuming it can be diagnosed accurately, whether treatment improves outcomes. This document replaces the document of the same name, last published in 2021 (Fertil Steril 2021;115(6):1416-23).
Practice Committee of the American Society for Reproductive Medicine, 2026·Fertility and Sterility
Current strategies for the assessment and treatment of recurrent pregnancy loss are discussed. This replaces the previous document, titled, "Evaluation and treatment a committee opinion," last published in 2012.